ReviewClinical, cosmetic and investigational dermatology2015
Pyoderma gangrenosum: challenges and solutions.
Review in Clinical, cosmetic and investigational dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Outcomes and Risk Factors of Pyoderma Gangrenosum After Reduction Mammoplasty: A Systematic Review of the Literature and Case Report.Aesthetic plastic surgery · 2025Pooled it
- Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study.The Journal of dermatology · 2022Trial
- Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty-six-week phase 3 open-label study.The Journal of dermatology · 2020Trial
- Pyoderma Gangrenosum Masquerading as Chronic Infective Ulcers: Two Case Reports Across Age Extremes.Clinical case reports · 2026Article
- Pyoderma gangrenosum following joint arthroplasty: a comprehensive review of clinical features, diagnosis, and management.Postepy dermatologii i alergologii · 2026Review
- The overlooked surface: cutaneous manifestations of inflammatory bowel disease.Translational gastroenterology and hepatology · 2026Review
- Pyoderma Gangrenosum Secondary to Melanotan.Cureus · 2025Article
- Pyoderma gangrenosum with complications of severe trigeminal neuralgia.JAAD case reports · 2025Article
- Pyoderma Gangrenosum in a Patient with Crohn's Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature.Clinics and practice · 2025Review
- Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: Interim analysis of a post-marketing observational study in Japan.The Journal of dermatology · 2025Observational
- Clinical characteristics, treatment, and wound management of pyoderma gangrenosum: A case series.PloS one · 2025Article
- Pyoderma Gangrenosum, a Challenging Postpartum Diagnosis-Case Report and Literature Review.Journal of clinical medicine · 2024Review
- The Histopathology of Leg Ulcers.Dermatopathology (Basel, Switzerland) · 2024Review
- Narrative Review: Pyoderma Gangrenosum.Cureus · 2024Review
- Recurrent Vegetative Pyoderma Gangrenosum of the Face: A Case Report.Acta medica Philippina · 2024Article
- Article
- Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative.Archives of dermatological research · 2023Article
- A Rare Complication Following Breast Conserving Surgery: Pyoderma Gangrenosum.European journal of breast health · 2023Article
- Review
- Pyoderma Gangrenosum Precipitated by Breast Engorgement Following Lactation Discontinuation: A Rare Case Report.Cureus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyoderma gangrenosum (PG) is a rare disease, but commonly related to important morbidity. PG was first assumed to be infectious, but is now considered an inflammatory neutrophilic disease, often associated with autoimmunity, and with chronic inflammatory and neoplastic diseases. Currently, many aspects of the underlying pathophysiology are not well understood, and etiology still remains unknown. PG presents as painful, single or multiple lesions, with several clinical variants, in different locations, with a non specific histology, which makes the diagnosis challenging and often delayed. In the classic ulcerative variant, characterized by ulcers with inflammatory undermined borders, a broad differential diagnosis of malignancy, infection, and vasculitis needs to be considered, making PG a diagnosis of exclusion. Moreover, there are no definitively accepted diagnostic criteria. Treatment is also challenging since, due to its rarity, clinical trials are difficult to perform, and consequently, there is no "gold standard" therapy. Patients frequently require aggressive immunosuppression, often in multidrug regimens that are not standardized. We reviewed the clinical challenges of PG in order to find helpful clues to improve diagnostic accuracy and the treatment options, namely topical care, systemic drugs, and the new emerging therapies that may reduce morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.